North American Vaccine Inc. said Friday that it has beenawarded a contract for the production of DTP vaccine from theNational Institute of Child Health and Human Development.
The contract runs from March 1 through Jan. 31, 1993. AmVax(AMEX:NVX) said it will receive about $1.6 million in funds thisyear.
The diphtheria, tetanus and pertussis vaccine is in Phase IIItrials in Sweden. The NICHD plans to conduct in 1993 a safetyand immunogenicity trial to gather U.S. data. The U.S. trial willbe used to back up the Swedish data in support of a late 1993filing for U.S. marketing approval, said company counsel DanielAbdun-Nabi.
Shares of the Beltsville, Md., company rose 25 cents to $9.88 onFriday.
(c) 1997 American Health Consultants. All rights reserved.